<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02127125</url>
  </required_header>
  <id_info>
    <org_study_id>HSC20130458H</org_study_id>
    <nct_id>NCT02127125</nct_id>
  </id_info>
  <brief_title>Mechanism of Microbiome-induced Insulin Resistance in Humans (Aim2)</brief_title>
  <acronym>MicroB2</acronym>
  <official_title>Mechanism of Microbiome-induced Insulin Resistance in Humans (Aim2)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The University of Texas Health Science Center at San Antonio</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>American Diabetes Association</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>The University of Texas Health Science Center at San Antonio</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether microbiome modulation and an experimental
      reduction in plasma LPS concentration improve inflammation and insulin action in insulin
      resistant (obese and T2DM) subjects.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In this Aim we will test the hypothesis that lowering lipopolysaccharide (LPS) concentration
      in the circulation will improve systemic (muscle) inflammation and glucose metabolism in
      insulin resistant (obese and T2DM) subjects by protecting the intestinal barrier with a
      synbiotic (Bifidobacterium longum R0175 and oligofructose) or by sequestering LPS in the
      gastrointestinal lumen with sevelamer.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>April 2014</start_date>
  <completion_date type="Anticipated">December 2019</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Insulin sensitivity</measure>
    <time_frame>Change from baseline insulin sensitivity at 28 days of the intervention.</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Plasma endotoxin level and its panel.</measure>
    <time_frame>Change from baseline plasma endotoxin level and its panel during 28 days.</time_frame>
    <description>Plasma Lipopolysaccharide (LPS), LPS binding protein (LBP), soluble cluster of differentiation (CD)14, interleukin (IL)-6, and tumor necrosis factor (TNF)-alpha.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Gut permeability</measure>
    <time_frame>Change from baseline gut permeability at 24 days of the intervention.</time_frame>
    <description>urine for lactulose and mannitol ratio.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">108</enrollment>
  <condition>Insulin Sensitivity</condition>
  <arm_group>
    <arm_group_label>Type2 Diabetes Mellitus</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Type 2 Diabetes Mellitus (36 completers)
12 subjects will receive the synbiotic
12 subjects will receive sevelamer
12 subjects will receive maltodextrin (placebo)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Obese with NGT</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Obese (BMI = 30-37 kg/m2) normal glucose tolerant (36 completers)
12 subjects will receive the synbiotic
12 subjects will receive sevelamer
12 subjects will receive maltodextrin (placebo)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Lean with NGT</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Lean (BMI&lt; 26 kg/m2) normal glucose tolerant (36 completers)
12 subjects will receive the synbiotic
12 subjects will receive sevelamer
12 subjects will receive maltodextrin (placebo)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Maltodextrin</intervention_name>
    <description>Maltodextrin treatment as a placebo group. Maltodextrin, 6 gm three times a day for 4 weeks.</description>
    <arm_group_label>Type2 Diabetes Mellitus</arm_group_label>
    <arm_group_label>Obese with NGT</arm_group_label>
    <arm_group_label>Lean with NGT</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Synbiotic</intervention_name>
    <description>Synbiotic [5 g of oligofructose + 1 g Bifidobacterium longum R0175 (4 billion colony forming unit (CFU)/g) three times a day) for 4 weeks.</description>
    <arm_group_label>Type2 Diabetes Mellitus</arm_group_label>
    <arm_group_label>Obese with NGT</arm_group_label>
    <arm_group_label>Lean with NGT</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sevelamer</intervention_name>
    <description>Sevelamer (1.6 g sevelamer + 4.4 g maltodextrin three times a day), for 4 weeks</description>
    <arm_group_label>Type2 Diabetes Mellitus</arm_group_label>
    <arm_group_label>Obese with NGT</arm_group_label>
    <arm_group_label>Lean with NGT</arm_group_label>
    <other_name>Renvela</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Both genders (50%, male). All races and ethnic groups.

          -  Premenopausal women in the follicular phase, non-lactating, and with a negative
             pregnancy test. Postmenopausal women on stable dose of or not exposed to hormone
             replacement for ≥6 months.

          -  Hematocrit (HCT)≥ 34%, serum creatinine ≤ 1.4 mg/dl, and normal results of serum
             electrolytes, urinalysis, and coagulation tests. Liver function tests (LFTs) up to 2
             times normal

          -  Stable body weight (±2%) for ≥ 3 months.

          -  Two or less sessions of strenuous exercise/wk for last 6 months.

        Exclusion Criteria:

          -  Current treatment with drugs known to affect glucose and lipid homeostasis. If the
             subject has been on a stable dose for the past 3 months, the following agents will be
             permitted: calcium channel blockers, β-blockers, ACE inhibitors, angiotensin receptor
             blockers, and statins

          -  History of allergy to sevelamer.

          -  Non-steroidal anti-inflammatory drugs or systemic steroid use for more than a week
             within 3 months.

          -  Current treatment with anticoagulants (warfarin). Aspirin (up to 325 mg) and
             clopidogrel will be permitted if these can be held for seven days prior to the biopsy
             in accordance with the primary physician.

          -  Use of agents that affect gut flora (e.g. antibiotics, colestyramine, lactulose, PEG)
             within 3 months.

          -  History of heart disease (New York Heart Classification greater than grade II; more
             than non-specific ST-T wave changes on the ECG), peripheral vascular disease,
             pulmonary disease, smokers.

          -  Poorly controlled blood pressure (systolic BP&gt;170, diastolic BP&gt;95 mmHg).

          -  Active inflammatory, autoimmune, hepatic, gastrointestinal, malignant, and psychiatric
             disease.

          -  History of gastrointestinal surgery or gastrointestinal obstruction within two years.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nicolas Musi, MD.</last_name>
    <role>Principal Investigator</role>
    <affiliation>The University of Texas Health Science Center at San Antonio</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Nicolas Musi, MD.</last_name>
    <phone>210-630-5001</phone>
    <email>musi@uthscsa.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Lauri Che Kelly, RN</last_name>
    <phone>210-617-5300</phone>
    <phone_ext>14731</phone_ext>
    <email>che@uthscsa.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Audie L. Murphy VA Hospital, STVHCS</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nicolas Musi, MD.</last_name>
      <phone>210-617-5300</phone>
      <phone_ext>15197</phone_ext>
      <email>Musi@uthscsa.edu</email>
    </contact>
    <contact_backup>
      <last_name>Lauri Che Kelly, RN</last_name>
      <phone>210-617-5300</phone>
      <phone_ext>14731</phone_ext>
      <email>sathavarodom@uthscsa.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Nicolas Musi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 24, 2014</study_first_submitted>
  <study_first_submitted_qc>April 28, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 30, 2014</study_first_posted>
  <last_update_submitted>March 21, 2018</last_update_submitted>
  <last_update_submitted_qc>March 21, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 23, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>The University of Texas Health Science Center at San Antonio</investigator_affiliation>
    <investigator_full_name>Nicolas Musi</investigator_full_name>
    <investigator_title>Nicolas Musi</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin Resistance</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sevelamer</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

